The 11 analysts offering 12-month price forecasts for BridgeBio Pharma Inc have a median target of 50.00, with a high estimate of 60.00 and a low estimate of 28.00. The median estimate represents a +74.09% increase from the last price of 28.72.
The current consensus among 12 polled investment analysts is to Buy stock in BridgeBio Pharma Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.72
Reporting Date Feb 22
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.